Seeking Alpha

Bristol-Myers Squibb (BMY) and AstraZeneca (AZN) win the battle for Amylin (AMLN), agreeing to...

Bristol-Myers Squibb (BMY) and AstraZeneca (AZN) win the battle for Amylin (AMLN), agreeing to buy the diabetes drug maker for $31/share (10% premium to Friday's close). The total size of the deal is $7B, and includes about $3.4B from AZN, which will expand its diabetes collaboration with Bristol. (PR)
Comments (7)
  • ralphey
    , contributor
    Comments (342) | Send Message
     
    and Icahn wanted us to sell at $22 .... but he is brilliant you know
    30 Jun 2012, 10:12 AM Reply Like
  • norjud
    , contributor
    Comments (204) | Send Message
     
    Unless this company has good drugs in the pipeline it's a bust. Anything AZ touches turns to cr*p...
    30 Jun 2012, 10:48 AM Reply Like
  • smurf
    , contributor
    Comments (3950) | Send Message
     
    Really? Good dividend and growth history, low payout ratio, tons of cash, stellar credit rating, and great profitability.

     

    What exactly is it you don't like about them?
    30 Jun 2012, 12:04 PM Reply Like
  • Stone Fox Capital
    , contributor
    Comments (6073) | Send Message
     
    How is the payout ratio low? Company pays out $1.36 and only expected to make $1.9 this year and less next.
    30 Jun 2012, 01:58 PM Reply Like
  • smurf
    , contributor
    Comments (3950) | Send Message
     
    TTM earnings were $6.52. I don't use projected figures. They are nothing more than educated guesses.

     

    Dividend was $3.90.

     

    Payout ratio 59.8%. This is in line with ABT and some other stellar performers.
    1 Jul 2012, 12:58 AM Reply Like
  • norjud
    , contributor
    Comments (204) | Send Message
     
    You might be right on the dividend area..but the way the company is managed stinks to high heaven...look at all the $$$$$ Billions paid in fines over the last 5 years. They bought the the company that made the flu mist and that bombed....they have Crestor the best statin and screwed up it's launch. They took Prilosec 20mg and turned it into Nexium 40mg and the results were better...no kidding it's twice the dose. They are the laughing stock of pharma. The old CEO of Astra was caught having sex with employee's...don't get me started.
    30 Jun 2012, 12:30 PM Reply Like
  • smurf
    , contributor
    Comments (3950) | Send Message
     
    AZN may be the laughingstock of pharma on Nexium, but they're laughing at the consumers who are buying it. Agree that it is a sham drug, but wildly successful.

     

    Crestor has stabilized since the botched launch.

     

    I don't think AZN has hit any more speed bumps or has any more issues than any other of the big pharma outfits.
    1 Jul 2012, 01:02 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|